- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: Ajovy® | fremanezumab-vfrm | LBR-101 | PF-04427429 | PF-4427429 | RI-307 | RN-307 | RN307 | TEV-48125
fremanezumab is an approved drug (FDA (2018), EMA (2019))
Compound class: Antibody
Comment: Fremanezumab (TEV-48125) is a humanised IgG2a monoclonal antibody targeting calcitonin gene-related peptide (CGRP) [3,5], a peptide known to play a role in causing migraines. TEV-48125 was originally formulated as an intravenous agent, but has been re-formulated to allow sub-cutaneous administration. Anti-CGRP antibodies are being developed as an alternative to CGRP receptor antagonists (such as telcagepant) which have already been shown to effectively reduce migraine headache and inhibit neurogenic vasodilatation in humans, and validated the CGRP/CGPR pathway as a target for the acute and preventive treatments of migraine . Anti-CGRP antibodies have the advantage of longer half-lives compared to small molecule antagonists and are expected to exhibit fewer toxicities attributed to off-target interactions, toxitities which have thwarted the development of CGRP receptor antagonists.
The original patent claiming anti-CGRP antibodies held by Rinat Neuroscience Corp. who originally developed TEV-48125 (as RN307) is WO2007054809 .
Fremanezumab is the second CGRP/CGPR pathway targeting agent to receive marketing authorisation, following approval of the anti-CGPR monoclonal erenumab earlier in 2018.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
|Approved drug?||Yes (FDA (2018), EMA (2019))|
|International Nonproprietary Names|
|Ajovy® | fremanezumab-vfrm | LBR-101 | PF-04427429 | PF-4427429 | RI-307 | RN-307 | RN307 | TEV-48125|
|GtoPdb PubChem SID||315661284|
|Search PubMed clinical trials||fremanezumab|
|Search PubMed titles||fremanezumab|
|Search PubMed titles/abstracts||fremanezumab|